Circio Holding ASA (FRA:TA50)
€ 0.0006 0 (0%) Market Cap: 3.16 Mil Enterprise Value: 5.87 Mil PE Ratio: 0.98 PB Ratio: 0 GF Score: 1/100

Q1 2022 Targovax ASA Earnings Call Transcript

May 12, 2022 / 08:00AM GMT
Release Date Price: €4.33 (-5.63%)
Erik Digman Wiklund
Targovax ASA - CEO

Welcome to Targovax and our first quarter update. My name is Erik Digman Wiklund and I am the CEO. With me today, I have Chief Financial Officer, Lubor Gaal; as well as our Chief Medical Officer, Lone Ottesen. During the first quarter, we made major advances in delivering on our new strategy. Most importantly, we formed 2 critical business development deals with our new partners at Agenus. #1, announced yesterday is a clinical collaboration agreement on the next melanoma trial and Agenus will in this trial partner up with us and give us access to 2 important checkpoint inhibitors, their anti-PD-1 and their anti-CTLA-4, which we will combine ONCOS-102 with in our upcoming Phase II trial. This is an essential collaboration to be able to execute the trial and it will save us significant costs. And in addition, it gives us access to, particularly with the CTLA-4, 1 of the most interesting checkpoint inhibitors in development at the moment.

So we're very excited about this partnership and we think it will put ONCOS-102 in a position to really differentiate and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot